<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02445924</url>
  </required_header>
  <id_info>
    <org_study_id>2858/11/14</org_study_id>
    <nct_id>NCT02445924</nct_id>
  </id_info>
  <brief_title>Micro RNA Genetic Signature in NSCLC Egyptian Patients</brief_title>
  <official_title>Micro RNA Genetic Signature in Non-small Cell Lung Cancer Egyptian Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adel Salah Bediwy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be carried out on 40 subjects at Chest department Tanta university hospital&#xD;
&#xD;
      The subjects will be classified into three groups:&#xD;
&#xD;
        -  Group I: will include ten non smoker volunteers (control group I).&#xD;
&#xD;
        -  GroupII: will include ten smoker volunteers (control groupII).&#xD;
&#xD;
        -  Group III: will include twenty NSCLC patients confirmed by pathological examination of&#xD;
           bronchoalveolar examination (BAL), brush and/or biopsy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients and control groups will be subjected to the following:&#xD;
&#xD;
        -  Complete history taking and complete general examination.&#xD;
&#xD;
        -  Complete chest examination.&#xD;
&#xD;
        -  Radiological assessment including chest x ray (posteroanterior and lateral view).&#xD;
&#xD;
        -  Computed tomography (CT) chest for all patients in group III and when needed in group I&#xD;
           and II.&#xD;
&#xD;
        -  Laboratory investigations:&#xD;
&#xD;
             -  Complete blood picture&#xD;
&#xD;
             -  Fasting and post parandial blood sugar level&#xD;
&#xD;
             -  liver function tests&#xD;
&#xD;
             -  kidney function tests (urea and creatinine).&#xD;
&#xD;
             -  Prothrombine time and activity.&#xD;
&#xD;
             -  Zeil-Neelsen staining of sputum.&#xD;
&#xD;
             -  Tumour markers including Î± Fetoprotein, Carcino Embryonic antigen (CEA), CA19-9, CA&#xD;
                125, CA15-3 and others.&#xD;
&#xD;
        -  Venous blood samples will be collected from peripheral blood (5 ml) under complete&#xD;
           aseptic technique. Serum samples will be obtained by centrifugation. Isolation of total&#xD;
           RNA from serum pools will be performed. RNA profiles and quantification will be assessed&#xD;
           using Microarray.&#xD;
&#xD;
        -  Lung biopsy either transbronchial via bronchoscopy or peripherally via ultrasound , CT&#xD;
           guided, thoracoscopy or open lung biopsy will be performed with isolation of total RNA&#xD;
           from lung tissue biopsy. RNA profiles and quantification will be assessed using&#xD;
           Microarray.&#xD;
&#xD;
        -  Bronchoalveolar lavage will be performed with isolation of total RNA from it. RNA&#xD;
           profiles will be assessed using Microarray.&#xD;
&#xD;
      Ethical considerations:&#xD;
&#xD;
        1. Informed consent will be taken from all subject's and include:&#xD;
&#xD;
           A. The aim of research. B. All data are confidential. C. All data will be used in&#xD;
           research only.&#xD;
&#xD;
        2. For patient's privacy:&#xD;
&#xD;
           A. There will be a code number for each patient in special folder. B. The results of&#xD;
           research will be used in scientific publishing only.&#xD;
&#xD;
        3. Unexpected risks that appear during the courses of research will be cleared to the&#xD;
           participants and the ethical committee on time.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detect micro RNA genetic signature pattern in non-small cell lung cancer Egyptian patients assessed using Microarray</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Control group 1</arm_group_label>
    <description>ten non smoker volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group 2</arm_group_label>
    <description>ten smoker volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSCLC patients</arm_group_label>
    <description>twenty NSCLC patients confirmed by pathological examination of bronchoalveolar examination (BAL), brush and/or biopsy</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, bronchial lavage, bronchial biopsies&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study will be carried out on 40 subjects at Chest department Tanta university&#xD;
        hospital.&#xD;
&#xD;
        The subjects will be classified into three groups:&#xD;
&#xD;
          -  Group I: will include ten non smoker volunteers (control group I).&#xD;
&#xD;
          -  GroupII: will include ten smoker volunteers (control groupII).&#xD;
&#xD;
          -  Group III: will include twenty NSCLC patients confirmed by pathological examination of&#xD;
             bronchoalveolar examination (BAL), brush and/or biopsy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion criteria for patients:&#xD;
&#xD;
        Non small cell lung cancer patients recently diagnosed who did not receive chemotherapy,&#xD;
        surgery or radiation therapy.&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion criteria for patients:&#xD;
&#xD;
          -  Diagnosis of asthma or COPD.&#xD;
&#xD;
          -  Broncheiactasis.&#xD;
&#xD;
          -  upper/lower respiratory tract infection in the preceding 4 weeks.&#xD;
&#xD;
          -  Active pulmonary tuberculosis.&#xD;
&#xD;
          -  Associated cancer beside lung cancer.&#xD;
&#xD;
          -  Patients who received chemotherapy, surgery or radiation therapy previous to the&#xD;
             sample collection.&#xD;
&#xD;
        Exclusion criteria for control subjects:&#xD;
&#xD;
          -  Diagnosis of asthma or COPD.&#xD;
&#xD;
          -  Broncheiactasis.&#xD;
&#xD;
          -  Upper/lower respiratory tract infection in the preceding 4 weeks.&#xD;
&#xD;
          -  Active pulmonary tuberculosis&#xD;
&#xD;
          -  Smoking in group I.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amgad A Farahat, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chest Department, Faculty of Medicine, Tanta University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ayman H Abd El-Zaher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chest Department, Faculty of Medicine, Tanta University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Said M Hammad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Pathology Department, Faculty of Medicine, Tanta University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adel S Bediwy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chest Department, Faculty of Medicine, Tanta University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ayman A Al Saka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pathology Department, Faculty of Medicine, Tanta University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samar A Mansour, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chest Department, Faculty of Medicine, Tanta University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abdel-Aziz A Zidan, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director of Genomics and Proteomics Unit, Center of Excellence in Cancer Research, Tanta University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chest Department, Faculty of Medicine, Tanta University</name>
      <address>
        <city>Tanta</city>
        <state>Gharbia</state>
        <zip>31111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Tang D, Shen Y, Wang M, Yang R, Wang Z, Sui A, Jiao W, Wang Y. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer. Eur J Cancer Prev. 2013 Nov;22(6):540-8. doi: 10.1097/CEJ.0b013e32835f3be9.</citation>
    <PMID>23462458</PMID>
  </reference>
  <reference>
    <citation>Keller A, Leidinger P, Borries A, Wendschlag A, Wucherpfennig F, Scheffler M, Huwer H, Lenhof HP, Meese E. miRNAs in lung cancer - studying complex fingerprints in patient's blood cells by microarray experiments. BMC Cancer. 2009 Oct 6;9:353. doi: 10.1186/1471-2407-9-353.</citation>
    <PMID>19807914</PMID>
  </reference>
  <reference>
    <citation>Leidinger P, Keller A, Meese E. MicroRNAs - Important Molecules in Lung Cancer Research. Front Genet. 2012 Jan 23;2:104. doi: 10.3389/fgene.2011.00104. eCollection 2011.</citation>
    <PMID>22303398</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>May 13, 2015</study_first_submitted>
  <study_first_submitted_qc>May 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2015</study_first_posted>
  <last_update_submitted>October 21, 2016</last_update_submitted>
  <last_update_submitted_qc>October 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Adel Salah Bediwy</investigator_full_name>
    <investigator_title>Assistant Professor of Chest Diseases, Faculty of Medicine</investigator_title>
  </responsible_party>
  <keyword>genetic signature</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>micro RNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

